Dashboard
1
Poor Management Efficiency with a low ROCE of 5.34%
- The company has been able to generate a Return on Capital Employed (avg) of 5.34% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 1.35% and Operating profit at -186.72% over the last 5 years
3
The company has declared Negative results for the last 10 consecutive quarters
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,686 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.08
-2.17%
1.92
Revenue and Profits:
Net Sales:
42 Million
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.04%
0%
-22.04%
6 Months
53.69%
0%
53.69%
1 Year
60.7%
0%
60.7%
2 Years
16.39%
0%
16.39%
3 Years
4.09%
0%
4.09%
4 Years
-17.92%
0%
-17.92%
5 Years
-51.48%
0%
-51.48%
Shanghai Shen Lian Biomedical Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.35%
EBIT Growth (5y)
-186.72%
EBIT to Interest (avg)
42.56
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.20
Tax Ratio
13.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.34%
ROE (avg)
3.66%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.92
EV to EBIT
-58.03
EV to EBITDA
95.97
EV to Capital Employed
2.01
EV to Sales
8.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.46%
ROE (Latest)
-2.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
41.90
37.40
12.03%
Operating Profit (PBDIT) excl Other Income
3.30
-18.90
117.46%
Interest
0.10
0.00
Exceptional Items
1.20
0.10
1,100.00%
Consolidate Net Profit
-11.00
-33.30
66.97%
Operating Profit Margin (Excl OI)
-358.30%
-964.30%
60.60%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 12.03% vs -6.50% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 66.97% vs -464.41% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
299.00
297.10
0.64%
Operating Profit (PBDIT) excl Other Income
33.30
90.30
-63.12%
Interest
0.10
0.00
Exceptional Items
-27.30
0.10
-27,400.00%
Consolidate Net Profit
-48.70
29.90
-262.88%
Operating Profit Margin (Excl OI)
-118.00%
90.20%
-20.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.64% vs -8.64% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -262.88% vs -50.98% in Dec 2023
About Shanghai Shen Lian Biomedical Corp. 
Shanghai Shen Lian Biomedical Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






